Biomarin (BMRN) rockets 29% after saying that its GALNS drug met its main target in a Phase III...


Biomarin (BMRN) rockets 29% after saying that its GALNS drug met its main target in a Phase III trial of improving the walking ability of patients with the rare genetic disorder of Morquio A Syndrome. The drug is seen as the most important in BioMarin's pipeline, with the potential to double its revenue. (PR)

From other sites
Comments (1)
  • Paulo Santos
    , contributor
    Comments (33921) | Send Message
     
    Weeee, that thing already discounts quite a bit of happiness in the future.
    5 Nov 2012, 08:27 AM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs